The design and evaluation of low molecular weight peptide-based severe acute respiratory
syndrome (SARS) chymotrypsin-like protease (3CL) protease inhibitors are described. A …

The main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the cause of coronavirus disease (COVID-19), is an ideal target for pharmaceutical …

The coronavirus main protease (Mpro) is required for viral replication and has enzymatical
activity as a homodimer. Thus, targeting its dimerization is an effective strategy for …

The main peptidase (Mpro) from the coronavirus (CoV) causing severe acute respiratory
syndrome (SARS) is one of the most attractive molecular targets for the development of anti …

Structure-based design, synthesis, and biological evaluation of a series of peptidomimetic
severe acute respiratory syndrome-coronavirus chymotrypsin-like protease inhibitors are …

All coronaviruses, including the recently emerged Middle East respiratory syndrome
coronavirus (MERS-CoV) from the β-CoV subgroup, require the proteolytic activity of the …

Over 10 years have passed since the deadly human coronavirus that causes severe acute
respiratory syndrome (SARS-CoV) emerged from the Guangdong Province of China …

Background The etiological agent for the coronavirus illness outbreak in 2019–2020 is a
novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

In December 2019, the first cases of a novel coronavirus infection causing COVID-19 were
diagnosed in Wuhan, China. Viral Papain-Like cysteine protease (PLpro, NSP3) is essential …

β-coronavirus (CoVs) alone has been responsible for three major global outbreaks in the
21st century. The current crisis has led to an urgent requirement to develop therapeutics …